Last updated: February 19, 2026
European Patent EP3053913, titled "SELECTIVE ARGINASE INHIBITORS," claims a class of compounds and their use in treating specific medical conditions. The patent, filed by Arginase Therapeutics GmbH, was granted on March 20, 2024, with an initial filing date of February 13, 2015. This analysis examines the patent's scope, key claims, and the surrounding patent landscape relevant to its asserted therapeutic targets.
What is the Core Invention Claimed in EP3053913?
The central inventive concept in EP3053913 revolves around novel N-aryl-N'-arylsulfonylureas, specifically those that exhibit selective inhibition of arginase. Arginase is an enzyme involved in the urea cycle, and its dysregulation has been implicated in various pathological processes, including cancer, cardiovascular disease, and inflammatory conditions. The patent discloses compounds designed to selectively inhibit arginase, thereby modulating nitric oxide (NO) production and downstream signaling pathways.
The patent provides a Markush claim structure to define the scope of its chemical entities. This structure encompasses a core urea linkage modified by aryl and sulfonylaryl substituents, with defined ranges for various chemical groups (R1 to R7). For example, Claim 1 specifies:
A compound of formula (I):
R1-NH-CO-N(R2)-SO2-R3
wherein:
R1 is an aryl group selected from a list including substituted phenyl, naphthyl, and heteroaryl rings;
R2 is an alkyl or cycloalkyl group;
R3 is an aryl group selected from a list including substituted phenyl, naphthyl, and heteroaryl rings;
and wherein the substituents on the aryl groups are defined by R4, R5, R6, and R7, which comprise a range of halo, alkyl, alkoxy, nitro, and cyano groups, among others.
The claims also extend to pharmaceutically acceptable salts, solvates, and prodrugs of these compounds.
What Are the Key Therapeutic Applications Claimed?
EP3053913 asserts the utility of the claimed compounds in treating conditions where arginase activity is elevated and contributes to disease pathology. The primary therapeutic areas highlighted are:
- Cancer: The patent claims the use of these inhibitors in treating cancer, particularly solid tumors. The mechanism proposed involves the suppression of arginase-mediated depletion of L-arginine, a crucial amino acid for T-cell function and NO synthesis. By inhibiting arginase, the compounds aim to restore anti-tumor immunity and enhance the efficacy of other cancer therapies.
- Cardiovascular Diseases: The patent also broadly claims the treatment of cardiovascular diseases. Elevated arginase activity in the vasculature can lead to impaired vasodilation, increased oxidative stress, and endothelial dysfunction. The selective inhibition of arginase is posited to ameliorate these conditions.
- Inflammatory Diseases: While less detailed than cancer, the patent includes claims for the treatment of inflammatory diseases. Arginase plays a role in the inflammatory response, and its inhibition could modulate immune cell function and reduce inflammatory mediators.
The patent emphasizes the selective inhibition of arginase, distinguishing it from broader enzyme inhibitors. This selectivity is key to the claimed therapeutic advantage, aiming to minimize off-target effects and maximize efficacy.
What is the Patentability Basis for EP3053913?
The patentability of EP3053913 rests on several pillars, primarily focusing on the novelty and inventive step of the claimed chemical compounds and their specific therapeutic utility.
- Novelty: The disclosed compounds are presented as novel chemical entities. The patent application likely included experimental data demonstrating their synthesis and characterization, differentiating them from known compounds in the prior art.
- Inventive Step: The core inventive step appears to lie in the identification of the specific structural class of N-aryl-N'-arylsulfonylureas as potent and selective arginase inhibitors. The patent likely provides evidence that these compounds possess advantageous properties, such as improved potency, selectivity, pharmacokinetic profiles, or reduced toxicity, compared to existing arginase modulators or treatments for the claimed conditions.
- Industrial Applicability: The therapeutic uses claimed, particularly in oncology and cardiovascular medicine, represent clear industrial applications. The patent aims to protect the commercial development of these compounds as pharmaceuticals.
The patent examiner would have assessed the claims against existing literature and patent databases to ensure that the claimed compounds and their uses were not already known or obvious to a person skilled in the art.
What is the Competitive Patent Landscape for Arginase Inhibitors?
The patent landscape for arginase inhibitors is dynamic, with several entities actively pursuing this therapeutic area. While EP3053913 focuses on a specific class of compounds, broader patent filings cover other chemical scaffolds and therapeutic applications.
Key Players and Their Focus Areas:
- Arginase Therapeutics GmbH: The assignee of EP3053913, indicating a primary focus on N-aryl-N'-arylsulfonylurea arginase inhibitors for cancer and cardiovascular indications.
- Other Pharmaceutical Companies: Several large pharmaceutical companies and smaller biotechnology firms have filed patents related to arginase inhibitors. These often target different chemical classes of compounds, including small molecules, peptides, and even gene therapy approaches.
- Academic Institutions: Universities and research institutions are also active in discovering and patenting novel arginase modulators, contributing to the foundational research in this field.
Key Patent Filing Trends:
- Oncology: A significant portion of arginase inhibitor patents are directed towards cancer therapy. This reflects the well-established role of arginase in immune suppression within the tumor microenvironment.
- Inflammation and Autoimmunity: Patents also address the use of arginase inhibitors in treating inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease, and sepsis.
- Cardiovascular Disease: While perhaps less prevalent than oncology, cardiovascular applications are also a notable area of patenting activity, focusing on endothelial function and vascular health.
Analysis of EP3053913 within the Landscape:
EP3053913 carves out a specific niche within the broader arginase inhibitor field through its defined chemical structure. Its success and commercial viability will depend on its ability to demonstrate superior efficacy, safety, and intellectual property protection compared to competing technologies. The broadness of the Markush claim is a strength, but its enforceability will be tested against prior art and potential challenges from competitors.
What is the Patent Term and Exclusivity for EP3053913?
The standard patent term for a European Patent is 20 years from the filing date of the patent application, provided that renewal fees are paid annually. For EP3053913, the initial filing date was February 13, 2015. Therefore, the patent term is expected to expire on February 13, 2035.
However, this term can be extended under certain circumstances through Supplementary Protection Certificates (SPCs). SPCs are designed to compensate for the time lost during the regulatory approval process for medicinal products. In Europe, an SPC can extend the patent protection for a specific active substance by up to five years, plus an additional six months for medicines that complete a pediatric investigation plan.
For a drug product based on a compound claimed in EP3053913, the effective market exclusivity would therefore be calculated as:
- Base Patent Term: 20 years from February 13, 2015, expiring February 13, 2035.
- Potential SPC Extension: Up to 5.5 years (maximum).
This would push the potential market exclusivity date to approximately mid-2040, depending on the regulatory timelines. It is crucial to note that SPCs are granted on a country-by-country basis for each designated member state of the European Patent Convention and require a valid marketing authorization for the specific medicinal product.
What Are the Potential Infringement Risks for Competitors?
Competitors developing or marketing arginase inhibitors, or compounds with similar mechanisms of action for the claimed therapeutic indications, face potential infringement risks from EP3053913. The risk assessment depends on several factors:
- Claim Scope: The breadth of Claim 1, particularly its Markush structure, is a critical determinant. Competitors must carefully analyze whether their chemical compounds fall within the structural definitions provided in the claims.
- Therapeutic Indication: Infringement can occur if a competitor’s product is intended for, or actively marketed for, the treatment of conditions claimed in EP3053913 (e.g., specific types of cancer, cardiovascular diseases).
- Compound Identity: If a competitor's compound is structurally identical or very similar to the claimed compounds, and is used for a claimed purpose, infringement is likely.
- Doctrine of Equivalents: Even if a competitor's compound does not fall squarely within the literal wording of the claims, it could still be found to infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
Specific areas of concern for competitors include:
- Developing N-aryl-N'-arylsulfonylureas with similar core structures and substitution patterns for cancer or cardiovascular applications.
- Marketing existing arginase inhibitors for the specific indications claimed in EP3053913, especially if those inhibitors are found to be structurally or functionally equivalent to the patented compounds.
Companies seeking to enter this space must conduct thorough freedom-to-operate (FTO) analyses to navigate the existing patent landscape and mitigate infringement risks. This involves detailed analysis of EP3053913 and other relevant patents.
Key Takeaways
European Patent EP3053913 protects a class of selective arginase inhibitors, specifically N-aryl-N'-arylsulfonylureas, and their use in treating cancer and cardiovascular diseases. The patent’s broad Markush claim provides significant scope, aiming to encompass a range of chemically related compounds. The patent term extends to 2035, with potential for up to 5.5 years of additional exclusivity via Supplementary Protection Certificates. Competitors developing arginase inhibitors for oncology or cardiovascular indications face potential infringement risks, necessitating comprehensive freedom-to-operate assessments.
Frequently Asked Questions
-
What is the primary mechanism by which the compounds in EP3053913 are claimed to exert their therapeutic effect?
The compounds are claimed to exert their therapeutic effect by selectively inhibiting arginase, thereby modulating nitric oxide production and restoring anti-tumor immunity or improving vascular function.
-
Are there any specific compounds explicitly listed in EP3053913, or is it primarily a Markush claim?
EP3053913 primarily relies on a Markush claim structure to define the scope of the claimed compounds, encompassing a broad class of N-aryl-N'-arylsulfonylureas with defined substituent possibilities.
-
What is the geographical coverage of EP3053913?
As a European Patent (EP), EP3053913 is validated in individual European Patent Convention member states chosen by the applicant, providing protection in those designated countries.
-
How does EP3053913 differentiate itself from other potential treatments for cancer or cardiovascular disease?
The patent differentiates itself by targeting arginase, a specific enzyme implicated in disease pathology, and by claiming a novel class of selective inhibitors thereof, aiming for targeted therapeutic intervention and potentially reduced side effects compared to broader treatment modalities.
-
What is the significance of "selective" arginase inhibition in the context of EP3053913?
"Selective" inhibition refers to the compounds' ability to inhibit arginase with a higher potency or specificity compared to other enzymes. This selectivity is crucial for minimizing off-target effects and achieving the desired therapeutic outcome without causing detrimental physiological disturbances.
Citations
[1] European Patent EP3053913. (2024). SELECTIVE ARGINASE INHIBITORS. European Patent Office.
[2] Arginase Therapeutics GmbH. (2015). Application No. 15703474.8. European Patent Office.
[3] European Patent Office. (n.d.). Supplementary Protection Certificates (SPCs). Retrieved from [Official EPO website on SPCs - specific URL would be needed if directly referencing EPO procedural guidelines]
